Elawyers Elawyers
Washington| Change

Momenta Pharmaceuticals, Inc. v. Amphastar Pharmaceuticals, Inc., 1:11-cv-11681-NMG. (2018)

Court: District Court, D. Massachusetts Number: infdco20180220d91 Visitors: 23
Filed: Feb. 07, 2018
Latest Update: Feb. 07, 2018
Summary: PLAINTIFFS MOMENTA PHARMACEUTICALS, INC. AND SANDOZ INC.'S MOTION FOR JUDGMENT AS A MATTER OF LAW OR, IN THE ALTERNATIVE, A NEW TRIAL AS TO THE VALIDITY OF U.S. PATENT NO. 7,575,886 NATHANIEL M. GORTON , District Judge . Pursuant to Fed. R. Civ. P. 50(b), plaintiffs Momenta Pharmaceuticals, Inc. and Sandoz Inc. hereby renew their Rule 50(a) motion for judgment as a matter of law dismissing Amphastar's written description and enablement defenses on the ground the evidence at trial was insuf
More

PLAINTIFFS MOMENTA PHARMACEUTICALS, INC. AND SANDOZ INC.'S MOTION FOR JUDGMENT AS A MATTER OF LAW OR, IN THE ALTERNATIVE, A NEW TRIAL AS TO THE VALIDITY OF U.S. PATENT NO. 7,575,886

Pursuant to Fed. R. Civ. P. 50(b), plaintiffs Momenta Pharmaceuticals, Inc. and Sandoz Inc. hereby renew their Rule 50(a) motion for judgment as a matter of law dismissing Amphastar's written description and enablement defenses on the ground the evidence at trial was insufficient, as a matter of law, to support the jury's verdict. Alternatively, plaintiffs move, pursuant to Fed R. Civ. P. 59, for a new trial on the issues of written description and enablement because the jury's verdict was against the weight of the evidence and resulted in a miscarriage of justice.

The grounds for this motion are stated in the memorandum of law, filed herewith. For the convenience of the Court, plaintiffs are also filing an Appendix attaching the trial exhibits that are cited in the memorandum.

Motion denied.

Source:  Leagle

Can't find what you're looking for?

Post a free question on our public forum.
Ask a Question
Search for lawyers by practice areas.
Find a Lawyer